JPWO2023064282A5 - - Google Patents

Info

Publication number
JPWO2023064282A5
JPWO2023064282A5 JP2024522406A JP2024522406A JPWO2023064282A5 JP WO2023064282 A5 JPWO2023064282 A5 JP WO2023064282A5 JP 2024522406 A JP2024522406 A JP 2024522406A JP 2024522406 A JP2024522406 A JP 2024522406A JP WO2023064282 A5 JPWO2023064282 A5 JP WO2023064282A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538117A (ja
JP2024538117A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/046291 external-priority patent/WO2023064282A1/en
Publication of JP2024538117A publication Critical patent/JP2024538117A/ja
Publication of JPWO2023064282A5 publication Critical patent/JPWO2023064282A5/ja
Publication of JP2024538117A5 publication Critical patent/JP2024538117A5/ja
Pending legal-status Critical Current

Links

JP2024522406A 2021-10-13 2022-10-11 Ｗｅｅ１阻害剤と抗ｃｄ４７抗体との組み合わせ。 Pending JP2024538117A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163262466P 2021-10-13 2021-10-13
US63/262,466 2021-10-13
PCT/US2022/046291 WO2023064282A1 (en) 2021-10-13 2022-10-11 Combinations of wee 1 inhibitors and anti-cd47 antibodies.

Publications (3)

Publication Number Publication Date
JP2024538117A JP2024538117A (ja) 2024-10-18
JPWO2023064282A5 true JPWO2023064282A5 (https=) 2025-10-22
JP2024538117A5 JP2024538117A5 (https=) 2025-10-22

Family

ID=85987727

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522406A Pending JP2024538117A (ja) 2021-10-13 2022-10-11 Ｗｅｅ１阻害剤と抗ｃｄ４７抗体との組み合わせ。

Country Status (6)

Country Link
US (1) US20240261295A1 (https=)
EP (1) EP4415721A4 (https=)
JP (1) JP2024538117A (https=)
CN (1) CN118139625A (https=)
TW (1) TW202320758A (https=)
WO (1) WO2023064282A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
BR112023000350A2 (pt) 2020-07-09 2023-03-28 Recurium Ip Holdings Llc Sais e formas de um inibidor de wee1
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
US20220184087A1 (en) * 2019-03-28 2022-06-16 The Penn State Research Foundation Methods and compositions relating to treatment of cancer
CN114555123B (zh) * 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Similar Documents

Publication Publication Date Title
JP2021530451A5 (https=)
JPWO2020006264A5 (https=)
JP2005530736A5 (https=)
JP2021191784A5 (https=)
JP2006523216A5 (https=)
RU2017143776A (ru) Пролекарства альвоцидиба, имеющие повышенную биодоступность
EP1737472B1 (en) Effective treatment of tumors and cancer with triciribine
JP2017525730A5 (https=)
JP2020500862A5 (https=)
JP2010540556A5 (https=)
JPWO2023056421A5 (https=)
JP2009502743A5 (https=)
JP2021530444A5 (https=)
JP2020511467A5 (https=)
JP2018535989A5 (https=)
CN1466464A (zh) 癌症治疗药
JPWO2020092907A5 (https=)
JP2021530487A5 (https=)
JP2016501838A5 (https=)
JPWO2019214634A5 (https=)
JP2008536853A5 (https=)
JP2012526766A5 (https=)
JP2021516236A5 (https=)
JP2020514344A5 (https=)
JPWO2023064282A5 (https=)